Pharmaxis Announces Encouraging Results from Phase 1c Study of Topical Pan LOX Inhibitor in Established Skin Scars
23rd
May 23
Release Date: 23/05/2023 4:34pm
- Well tolerated with good safety profile
- Marked change in scar composition with 30% reduction in collagen content
- First ever proof that LOX inhibition reduces skin collagen underpins expansion of Pharmaxis and Professor Fiona Wood collaboration into new skin fibrosis indications
- No overall improvements in scar appearance seen at 3 months points to need for longer study in established scars
Categories: News and Media